AI biotech company accelerating drug discovery and development. Owkin is an AI biotechnology company that leverages artificial intelligence to accelerate drug discovery and development, optimize clinical trials, and create advanced diagnostic tools. By combining human expertise with cutting-edge AI, Owkin aims to bridge the gap between complex biological research and the development of new treatments, ultimately bringing innovative diagnostics and therapies to patients faster. The company serves the biopharma and academic research communities, focusing on areas such as oncology and other diseases. Owkin was founded in 2016 and is headquartered in New York City, New York, USA. As of recent reports, Owkin has grown significantly, raising over $300 million and achieving unicorn status.